Should Merck & Co. Inc.'s Keytruda be approved for a high-risk bladder cancer, practitioners may be forced to reconcile whether the possibility of delaying, rather than avoiding, a radical cystectomy would be a preferable option for patients.
Keytruda (pembrolizumab) is proposed for treatment of adults with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma-in-situ...





